MEMBRANOUS LUPUS NEPHROPATHY

三种免疫抑制药物的疗效和毒性 将在膜性狼疮患者中评估治疗方案 12 个月研究期间的肾病。 肾脏详细检查 功能、肾小球选择性通透性和肾活检 形态学将在开始和结束时进行 治疗。 系统性红斑狼疮患者， 肾病范围蛋白尿和活检记录为膜性 肾病将用隔日泼尼松治疗，并且将 被随机接受： a) 没有额外的治疗（对照 组），b）静脉脉冲环磷酰胺高达 1.0 克/次 平方米体表面积，每隔一个月一次，共 6 次 剂量，或 c) 口服环孢菌素 A 最多每平方米 200 毫克 每天的体表面积，总共 11 个月。 狼疮病 将监测活性、肾功能测试和药物毒性 密切。 分析将包括数量的比较 肾小球功能和病理学的良好结果 与药物相关的毒性出现在每个治疗组中 12个月的学习结束。

The efficacy and toxicity of three immunosuppressive drug regimens will be evaluated in patients with membranous lupus nephropathy over a 12 month study period. Detailed tests of renal function, glomerular permselectivity and kidney biopsy morphology will be conducted at the beginning and end of treatment. Patients with systemic lupus erythematosus, nephrotic range proteinuria and biopsy documented membranous nephropathy will be treated with alternate day prednisone and will be randomized to receive: a) no additional therapy (control group), b) intravenous pulse cyclophosphamide up to 1.0 gram per square meter body surface area every other month for 6 total doses, or c) oral cyclosporin A up to 200 mg per square meter body surface area daily for a total of 11 months. Lupus disease activity, renal function tests and drug toxicities will be monitored closely. Analysis will include comparison of the number of favorable outcomes of glomerular function and pathology as well as drug-related toxicities appearing in each treatment group at the end of 12 months of study.